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Abstract: Background and Objectives: Hot flushes and sleep disturbances are the most common
vasomotor symptoms (VMS) reported by postmenopausal women. Hormonal treatment is to date
referred to as the gold standard approach but not suitable for all the patients. Alternative treatments
are needed in case of a contraindication to menopausal hormone therapy (MHT), adverse side
effects, and poor compliance. Paroxetine salt is the only nonhormonal medication approved by
the US Food and Drug Administration for the management of VMS. Nonetheless, few trials with
low consensus are available about this topic. In this review, we aimed to evaluate the efficacy of
low-dose paroxetine therapy in the treatment of vasomotor hot flushes and night sleep disturbances in
postmenopausal women. Materials and Methods: We performed an electronic search from the beginning
of all databases to July 2019. All results were then limited to a randomized trial. Restrictions for
language or geographic location were not utilized. Inclusion criteria were randomized clinical trials
of physiological or surgical postmenopausal women experiencing hot flushes and sleep disturbances
who were randomized to either low-dose paroxetine or placebo (i.e., formulations without active
ingredients). The primary outcome evaluated was the mean weekly reduction of hot flushes. Results:
Five randomized clinical trials, including 1482 postmenopausal women, were analyzed. Significant
heterogeneity (I2 = 90%) between studies was noted. Hot flushes episodes were significantly reduced
in the treatment arm compared to placebo (mean difference (MD)−7.97 [−10.51, −5.92] episodes/week).
Results on the improvement on sleep were limited by being reported in only two studies; however,
no significant reduction of night-time awakenings was observed (MD, −0.40 awakenings/night
[−1.38, 0.58 CI]). Conclusions: Low-dose paroxetine is an effective treatment for vasomotor menopause
symptoms, including hot flushes.
Keywords: paroxetine; hot flushes; menopause; vasomotor symptoms; efficacy; sleep disturbances
1. Introduction
Menopausal age has a major impact on women’s life. Progressive reduction of ovarian production
of estrogens and progesterone develop several symptoms [1,2]. Although changing in intensity and
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frequency from a woman to another, those symptoms involve vasomotor symptoms (VMS) [3], sleep
disturbances, genitourinary syndrome of menopause (i.e., vulvovaginal atrophy) [4,5], and psychologic
and emotional disorders [6]. In case of surgical menopause, in which women undergo bilateral
oophorectomy before normal menopause, those symptoms are increased compared with the general
population [2].
The most common reason for complaint in women is VMS [7], VMS can be typically defined as the
presence of daytime hot flushes and “night-sweats” due to hormonal change in menopause, especially
hot flushes (or flashes in the USA) and night sweats, which profoundly affect women’s quality of life
and quality of sleep [3,6].
For those women, menopausal hormone therapy (MHT) is recognized as the first-line therapy [8];
however, alternative treatments are needed in case of a contraindication to MHT, adverse side effects,
and poor compliance [9]. Besides, there are also women who refuse hormonal treatment for a variety
of reasons, mainly due to their fear of increasing the risk of cancer or weight gain [10,11]. For this
reason, it is necessary to search for nonhormonal treatments from which women could benefit from.
Paroxetine is an antidepressant drug which belongs to the SSRI (selective serotonin reuptake
inhibitors) class. At high dose, it is used to treat major depressive disorders [12]. Its efficacy and safety
have been proved by several trials and reviews [13]. SSRIs like citalopram or escitalopram were the
first to be described effective in reducing VMS severity [14]. In 2013, the United States Food and Drug
Administration (US FDA) approved the usage of low-dose paroxetine for the management of hot
flushes and night sweats after the end of two phase III randomized trials. Low-dose paroxetine consists
of a 7.5 mg daily dose of paroxetine mesylate or a 12.5 mg single dose of paroxetine hydrochloride [15].
Since 2013, studies have been carried out to validate the efficacy of paroxetine on hot flushes and
sleep disturbances with different results [14–22]. For this reason, the study aim was to carry out a
systematic review and meta-analysis of randomized clinical trials in order to evaluate the effectiveness
of low-dose paroxetine on hot flushes reduction and its impact on night-time awakenings.
2. Materials and Methods
2.1. Search Strategy
We performed electronic research in Scopus, ClinicalTrials.gov, MEDLINE, EMBASE, the
PROSPERO International Prospective Register of Systematic Reviews, and the Cochrane Central
Register of Controlled Trials with the use of the following keywords: “paroxetine,” “hot flushes,”
“vasomotor symptoms,” “sleep,” and “menopause” from inception of each database to April 2019.
All results were then limited to “clinical trial.” Restrictions for language or geographic location were
not applied. Commentaries, editorials, letters, and abstracts were excluded from search in every
database. When needed, we obtained unpublished data directly contacting authors of the original
papers whenever methodology indicated that further outcome data were recorded.
2.2. Study Selection and Risk of Bias
Inclusion criteria were randomized clinical trials of symptomatic women with VMS in physiological
or surgical menopause who were experiencing hot flushes and sleep disturbances and were randomized
to low-dose paroxetine treatment. Exclusion criteria included quasi-randomized trials and trials in
women who were eligible for paroxetine but did not experience sleep disturbances, trial involving
high-dose paroxetine administration or other therapy regimens, trials involving premenopausal women,
and studies on women suffering from major depressive symptoms before menopause. We piloted
the abstraction forms, designed specifically for this review, starting on a sample of included articles.
Key characteristics abstracted included patient descriptors, setting, features of the treatment and
comparator, outcomes evaluation, study duration, mean follow-up, results, and quality elements.
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Two authors (A.S., M.L.V.) reviewed and classified all the abstracts independently. Agreement
regarding potential relevance was reached by consensus; the same two authors obtained full-text
copies of those papers and independently extracted relevant data about the study characteristics and
the reproductive outcomes. When found, all the inconsistencies were discussed by the reviewers and
consensus was reached by discussion with a third author (P.D.F.). In addition, authors were contacted
whenever information was not reported but the methodology indicated that such information would
have been recorded.
The meta-analysis was referred to follow the Preferred Reporting Item for Systematic Reviews and
Meta-analyses (PRISMA) statement [16]. The risk of bias in each of the included study was assessed by
means of the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions [22].
Review authors’ judgments were categorized as “low risk,” “high risk,” or “unclear risk” of bias.
2.3. Outcomes
An intention-to-treat approach was used for every part of the analysis; women were evaluated
in reference to the treatment group to which they were randomly allocated in the original trials.
The primary outcome was the reduction of hot flushes episodes as achieved as a mean weekly reduction
(mean and SD). Secondary outcomes were sleep interference reduction, calculated as mean nighttime
awakenings reduction (mean and SD), and adverse treatment effects (as achieved as number and
percentage from each study). We also carried out a subgroup analysis for the primary outcome between
women with surgical menopause and physiological menopause.
2.4. Data Analysis
The data analysis was carried out using Review Manager 5.3 (The Nordic Cochrane Centre
2014, Copenhagen, Denmark). The summary measures were reported as summary mean difference
(MD) with 95% of confidence interval (CI) using the random-effects model of Der Simonian and
Laird. I-squared (Higgins I2) greater than 0% was used to identify heterogeneity. P-value < 0.05 was
considered statistically significant.
3. Results
Initially, we were able to identify nine trials from full-text articles evaluating paroxetine as a
treatment for hot flushes in menopause [15,17–24]. Five studies were excluded because they were
nonrandomized or cross-over trials [17,18,20–22]. Four randomized clinical trials, that included 1482
women who were eligible using inclusion criteria for this meta-analysis, were analyzed by the authors.
Figure 1 shows the flow diagram (PRISMA template) of information through the different phases
of the review.
The overall risk of bias was judged as low. Most studies had granted a low risk of bias in selective
reporting and incomplete outcome data according to the Cochrane Collaboration’s tool. Four of the
five studies were double-blind randomized, leading to a low bias judgment (Figure 2). Statistically,
heterogeneity within the trials ranged from low to high with no inconsistency (I2 = 0%) for the
secondary outcomes and I2 = 90% for the primary outcome.
Main baseline characteristics of the five included trials are described in Table 1. A total of 1482 women
were included in quantitative analysis, 738 were randomized to the treatment (low-dose paroxetine)
group and 744 to the placebo group. All studies enrolled women with diurnal and nocturnal hot flushes
due to a postmenopausal hormonal status and related sleep disturbances as referred to night awakenings.
Four studies involved women with surgical or physiological menopause, Capriglione et al. [21] included
only women with a prior history of surgically treated gynecological cancer and subsequent surgical
menopause. Women who were randomized into the treatment group received one daily administration
of low-dose paroxetine (7.5 or 12.5 mg) for a minimum of 6 to a maximum of 16 months; meanwhile,
women into the placebo group received formulations without active ingredient for the same time frame.
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Table 1. Characteristics of the included studies.
Stearns 2003 [17] Simon 2013 [19];Pinkerton 2014 [23] Capriglione 2016 [21]
Location USA USA Italy
Sample size n.
(Treatment/Placebo) 228 (111/117) 1174 (585/589) 80(42/38)












with hot flushes and
sleep disturbances
Surgical postmenopausal




56.3 54.6 (5.73) 53.5 (5.71)




28.62 (5.73) 26.7 (4.62)
29.03 (5.51) 27.5 (4.71)
Follow-up 6 weeks 12 weeks 16 weeks





Abbreviations: SD: standard derivation; BMI: body mass index.
3.1. Synthesis of Results
Women who were treated with low-dose paroxetine had a significant reduction of hot flushes
episodes (evaluated as mean weekly reduction from baseline) compared to placebo (mean difference
−7.97 [−10.51, −5.42] episodes/week) (Figure 3) (Table 2).
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[−10.51, −5.42]Placebo −12.6 ± 5.4 −37.3 ± 12.1 −39.3 ± 3.1
Sleep interference reduction





−1.98 ± 1.21 −1.39 ± 0.32
0%
−0.40
[−1.38, 0.58]Placebo −1.56 ± 1.21 −1.01 ± 0.31
In Table 3 subgroup analysis is described, achieved reduction was −7.89 MD [−11.23, −4.81 CI]
for patients with physiological menopause and −7.63 MD [−10.15, −5.56 CI] for women with
surgical menopause.
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Table 3. Subgroup analysis for included studies.





















Abbreviations: MD: mean difference; CI: confidence interval.
Two randomized clinical trials evaluated the effects on nighttime awakenings. However, there
were no statistically significant differences about mean nighttime awakenings reduction between
paroxetine and placebo were evaluated (−0.40 episodes/night MD [−1.38, 0.58 CI]) (Figure 4).
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3.2. Heterogeneity
Together with a small number of studies, however, this systematic review also highlights the
significant heterogeneity present in the available studies. This might be related to the fact that
population characteristics were variable, as well as which was suboptimal in some of them. In addition,
variability was present in other characteristics of the eligible studies, such as the criteria used to
describe VMS, the definition of the outcome measures, and the mean follow-up period. It is important
to take into account this heterogeneity when interpreting the results of this meta-analysis. For this
reason, available data were analyzed with the use of a random-effects model, which uses a conservative
approach by acknowledging that the samples evaluated in the individual studies might not all originate
from the same population. At the same time, the subgroup analyses conducted in this meta-analysis
(surgical menopause vs. physiological menopause) might give the reader some insight about the
potential moderating effect of some of these characteristics on the observed effect sizes. Sensitivity
analysis on daily hot flushes reduction was conducted. Removing each study one by one reported the
analysis to be nonsignificant (p > 0.05). However, when Stearns et al. 2013 was removed from the pool,
heterogeneity (I2) fell from 90 to 0%. This may be related to a different paroxetine dosage (12.5 mg/day)
if compared to the other studies since no other substantial differences between populations were found.
4. Discussion
This meta-analysis of randomized trials evaluating (physiological or surgical) postmenopausal
women suffering from daily hot flushes and sleep disturbances showed that low-dosage paroxetine
is an effective treatment for the reduction of daily hot flushes; nonetheless, we did not find
paroxetine usage clinically significant in improving sleep parameters such as nighttime awakenings.
Furthermore, paroxetine was effective in reducing hot flushes both in women with physiological and
surgical menopause.
Simon et al. [19] reported that 50.3% of women reported at least one case of treatment-emergent
sleep-related adverse events (TEAEs) from low to moderate (i.e., insomnia, hypersomnia, incubus,
reduced sleep length). Stearns et al. [19] also reported that 10% of women experienced light headache
during treatment, although it was nonsignificant. Moreover, sporadic cases of dizziness and nausea
were found. Concerning adverse effects, trials included in this quantitative analysis did not found any
statistically significant differences between the two arms; women under paroxetine or under placebo
experienced same adverse effects at similar frequencies [17–21]. Although nausea or dizziness or
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hypersomnia have been found clearly as main adverse events in reviews that involved paroxetine for
major depressive syndromes, we did not find this evidence in our review. This observation could be
related to the low-dosage therapy regimen.
However, women who experience breast cancer or thromboembolic venous pathologies and,
therefore, not suitable for menopausal hormone therapy can benefit from the use of low-dose
paroxetine [22–24]. For this reason, the North American Menopause Society described paroxetine as
a first-choice drug for those non-suitable patients and for those who refuse hormonal therapy [25].
Together with VMS, paroxetine has been reported to be useful also in decreasing chronic pelvic pain in
pre, peri-, and postmenopausal women, leading to an improvement of social relationships, sexuality,
and mental health [26–32]
Other reviews also described and supported the usage of paroxetine for the reduction of hot
flushes, leading to similar conclusions [31,32]. However, the impact on sleep disturbances was not
considered. Nonetheless, they used to describe VMS deriving them from several different scales instead
of considering the full number of episodes and the mean weekly reduction. We believe that this kind
of approach is the clearest evidence of the efficacy of paroxetine against hot flashes. Furthermore, no
review considered a subgroup analysis dividing women with a surgical from physiological menopause.
For those reasons, we believed that an updated meta-analysis of RCTs was needed.
A strength of our study is that it involved only randomized double-blind trials. No open trial or
prospective study was considered during study selection. Although heterogeneity has been found in
the primary outcome, it is clear that confidence intervals detected overlap, leading to a good quality
of evidence.
Severe limitations of our meta-analysis can be found: studies involved in this review did
not state the difference between night and daytime VMS; also, the length of each VMS was not
evaluated. Furthermore, the low number of RCTs included, high heterogeneity, and the fact that the
outcomes of interest are not fully reported in each study may limit the results of this meta-analysis.
Moreover, low-dose paroxetine regimen used between studies ranged from 7.5 to 12 mg, for this reason,
a random-effect model was used in order to calculate MD and CI; more RCTs involving differences
between those two regimens are needed. Furthermore, it was not possible to evaluate publication
bias using a funnel plot since the number of studies involved was inferior to 10. Nonetheless, it is
also needed to highlight that three [17,19,23] of four studies of this meta-analysis were founded by
pharmaceutical companies.
5. Conclusions
Low-dosage paroxetine can be useful in the reduction of vasomotor symptoms such as hot
flushes in physiological or surgical postmenopausal women. In two RCTs, no improvement of sleep is
observed for those women, although the description of sleep-related outcomes is often shifted by the
subjective opinions of the patient. Additional studies are required to assess the efficacy of paroxetine
on sleep disturbance.
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